Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05919264Phase 2Recruiting
- Sponsor
- Parabilis Medicines
- Start
- May 2023
- Primary completion
- Apr 2027
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of zolucatetide in solid tumor, colorectal cancer (CRC), hepatocellular carcinoma (HCC), desmoid tumor, prostate cancer (PCa), sponsored by Parabilis Medicines. Started May 2023; status: recruiting.
02
Drugs
zolucatetide
03
Conditions
solid tumorcolorectal cancer (CRC)hepatocellular carcinoma (HCC)desmoid tumorprostate cancer (PCa)
Beyond the preview
Go deeper on NCT05919264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05919264.